PC945 is the only potent, novel triazole anti-fungal that has been specifically developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, retention in lung tissues that offers a long duration of action and minimal systemic exposure.
PC945 is 30- to 100-fold more potent than voriconazole against Aspergillus fumigatus and exhibits minimal systemic bioavailability after inhaled administration and is intended for delivery by a standard, off-the-shelf nebulizer.
A phase 1 clinical trial of PC945 was completed in 2018.
PC945 has been used on a “special needs” basis in patients who have not responded to multiple standard-of-care (SOC) antifungal therapies, with extraordinary results. As of July 2020, of the nine (9) patients treated, positive clinical results were observed in eight (8) patients.
A Phase 3 study of PC945 for adults, who have limited or no alternative treatment options, for the treatment of invasive pulmonary aspergillus disease as part of a combined antifungal regimen will be initiated in 2021.
“On the back of our previous success in the inhaled therapeutic area, we set out with the goal of creating novel therapies for devastating lung diseases, specifically those that have a lack of viable and effective therapeutic options.”Dr Garth Rapeport
“The products that we are developing have the potential to make significant improvements in the standard of care for patients, effectively transforming chronic and crippling conditions in vulnerable populations, into treatable and manageable diseases.”Pete Strong